CDC awards Labcorp SARS-CoV-2 sequencing contract
January 8, 2021 -- The U.S. Centers for Disease Control and Prevention (CDC) has awarded Labcorp a contract to provide genomic sequencing of samples of the SARS-CoV-2 virus.
Co-Diagnostics develops test for mutated COVID-19 strain in U.K.
December 22, 2020 -- Co-Diagnostics announced that it has developed a molecular test for mutations that have been associated with a new variant of the coronavirus that has been causing alarm.
Bayer and Veracyte team up on thyroid cancer genomic profiling
December 22, 2020 -- Bayer and Veracyte are planning to work together on the genetic testing of patients with metastatic thyroid cancer. They will target patients whose disease is radioactive iodine refractory and who may be candidates for therapies targeted at particular mutations.
Test identifies any infection from any sample in hours
November 11, 2020 -- A new rapid test can identify any infection from any type of bodily fluid in as few as six hours, possibly changing the way diseases are diagnosed and treated, according to a study published November 9 in Nature Medicine.
Exact to acquire early cancer detection firm for $2B
October 28, 2020 -- Exact Sciences has agreed to acquire early cancer detection firm Thrive Earlier Detection in a deal worth up to $2.15 billion in cash and stock. The company also announced a second deal to acquire epigenetics firm Base Genomics.
MammaPrint cancer recurrence test secures reimbursement in Germany
October 21, 2020 -- California-based Agendia's MammaPrint 70-gene breast cancer recurrence test is set for reimbursement in Germany following a positive opinion for coverage by the country's Federal Joint Committee, or GB-A.
Paragon debuts more COVID-19 NGS tests
October 19, 2020 -- Precision medicine firm Paragon Genomics has debuted two additional CleanPlex next-generation sequencing (NGS) tests to detect the novel coronavirus and estimate disease severity.
AbbVie gets FDA nod for new use of Venclexta
October 19, 2020 -- AbbVie has announced that the U.S. Food and Drug Administration (FDA) approved a new use of its B-cell lymphoma 2 inhibiting drug venetoclax (Venclexta) in the treatment of acute myeloid leukemia for some patients.
Holy Grail: Ilumina nabs cancer testing firm in $8B deal
September 21, 2020 -- Illumina has agreed to acquire cancer diagnostics startup Grail for $8 billion in cash and stock. Grail utilizes Illumina's next-generation sequencing (NGS) technology, data science, and machine learning to identify cancer signals in blood samples.
Genetic testing cut adverse events in heart patients
August 27, 2020 -- Personalized genetic testing led to a 34% decrease in the number of patients who had serious adverse events following balloon angioplasties, according to results published August 25 in the Journal of the American Medical Association.  Discuss